Differential immunoreactivity of her-2/neu oncoprotein in prostatic tissues
- PMID: 1285216
- DOI: 10.1016/0960-7404(92)90028-j
Differential immunoreactivity of her-2/neu oncoprotein in prostatic tissues
Abstract
To investigate HER-2/neu oncoprotein immunoreactivity, monoclonal antibody TA1 immunohistochemical examination of flash-frozen radical prostatectomy specimens was performed (n = 35). All prostatic specimens contained benign prostatic hyperplasia (BPH) and/or prostatic intraepithelial neoplasia (PIN), as well as prostatic carcinoma (CaP). HER-2/neu oncoprotein immunoreactivity in BPH tissues was not significantly different than that for the PIN basal cell layer (P = 0.10) or for the PIN luminal cells (P = 0.17). There was significantly more HER-2/neu oncoprotein immunoreactivity in BPH than in areas of CaP (P < 0.001). There was no significant difference in the amount of immunoreactivity present in PIN basal cells when compared to the PIN luminal cells (P = 0.49). Both the PIN basal cells and luminal cells stained for the HER-2/neu oncoprotein to a higher degree than cells in the CaP areas (P < 0.001 in both cases). HER-2/neu oncoprotein immunoreactivity is present at a significantly higher degree in BPH and PIN than in malignant prostatic epithelium.
Similar articles
-
Differential immunoreactivity of epidermal growth factor receptor in benign, dysplastic and malignant prostatic tissues.J Urol. 1993 Jan;149(1):170-3. doi: 10.1016/s0022-5347(17)36032-9. J Urol. 1993. PMID: 7678041
-
Immunohistochemical expression of topoisomerase II alpha and Her-2/neu in prostatic carcinoma and benign prostatic hyperplasia.J Egypt Natl Canc Inst. 2008 Jun;20(2):158-67. J Egypt Natl Canc Inst. 2008. PMID: 20029472
-
Immunohistochemical study of the expression of epidermal growth factor receptor in benign prostatic hypertrophy, prostatic intraepithelial neoplasia and prostatic carcinoma.Indian J Pathol Microbiol. 2006 Oct;49(4):495-9. Indian J Pathol Microbiol. 2006. PMID: 17183836
-
Transforming growth factor-beta expression in prostate neoplasia.Anal Quant Cytol Histol. 2000 Feb;22(1):1-10. Anal Quant Cytol Histol. 2000. PMID: 10696454
-
Expression of the c-erbB-2 (HER-2/neu) oncoprotein in human prostatic carcinoma.J Urol. 1993 Nov;150(5 Pt 1):1427-33. doi: 10.1016/s0022-5347(17)35799-3. J Urol. 1993. PMID: 8105108 Review.
Cited by
-
Revisiting HER2 in Prostate Cancer from an Inclusive Perspective: From Biomarkers to Omics.Cancers (Basel). 2024 Sep 25;16(19):3262. doi: 10.3390/cancers16193262. Cancers (Basel). 2024. PMID: 39409883 Free PMC article. Review.
-
HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer.Proc Natl Acad Sci U S A. 2011 Sep 27;108(39):16392-7. doi: 10.1073/pnas.1101263108. Epub 2011 Sep 19. Proc Natl Acad Sci U S A. 2011. PMID: 21930937 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous